These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 3098043)

  • 1. Population analysis of susceptibility to ciprofloxacin and nalidixic acid in Staphylococcus, Pseudomonas aeruginosa, and Enterobacteriaceae.
    Søgaard P; Gahrn-Hansen B
    Acta Pathol Microbiol Immunol Scand B; 1986 Oct; 94(5):351-6. PubMed ID: 3098043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin.
    Kresken M; Wiedemann B
    Antimicrob Agents Chemother; 1988 Aug; 32(8):1285-8. PubMed ID: 3142353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of the new 4-quinolone compound Ro 23-6240.
    Clarke AM; Zemcov SJ
    Eur J Clin Microbiol; 1987 Apr; 6(2):161-4. PubMed ID: 3109895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibility of nosocomial Pseudomonas aeruginosa, enterobacteriaceae, and staphylococci to ciprofloxacin and ten other broad-spectrum antibiotics.
    Weinstein RA; Nathan C; Delzell D; Kabins SA
    Chemioterapia; 1987 Oct; 6(5):315-8. PubMed ID: 3123078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activity of the new fluoroquinolone BMY-40062.
    Chin NX; Neu H
    Eur J Clin Microbiol Infect Dis; 1990 Aug; 9(8):620-4. PubMed ID: 2120060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
    Guimaraes MA; Noone P
    J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises.
    Thomson KS; Sanders CC; Hayden ME
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2329-34. PubMed ID: 1804005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents.
    Manek N; Andrews JM; Wise R
    Antimicrob Agents Chemother; 1986 Aug; 30(2):330-2. PubMed ID: 3094444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of PD 127,391, an enhanced-spectrum quinolone.
    Wise R; Ashby JP; Andrews JM
    Antimicrob Agents Chemother; 1988 Aug; 32(8):1251-6. PubMed ID: 3142350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Susceptibility of methicillin-sensitive and methicillin-resistant staphylococci to ciprofloxacin].
    Namysł E; Piechowicz L; Krzywińska E; Galiński J
    Med Dosw Mikrobiol; 1993; 45(2):149-52. PubMed ID: 8309287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
    Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
    Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of meropenem against ciprofloxacin-resistant enterobacteriaceae and Pseudomonas aeruginosa.
    Garcia-Rodriguez JA; Blazquez AM; Fresnadillo MJ; Garcia Sanchez E; Garcia Sanchez JE; Trujillano Martin I
    J Chemother; 1996 Oct; 8(5):358-64. PubMed ID: 8957715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [In vitro antibacterial activity of a new fluoroquinolone, fleroxacin as a function of the sensitivity or resistance to nalidixic acid and to pefloxacin].
    Soussy CJ; Leclercq R; Deforges L; Duval J
    Pathol Biol (Paris); 1989 May; 37(5):364-9. PubMed ID: 2506511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Nationwide sensitivity surveillance of ciprofloxacin and various parenteral antibiotics against bacteria isolated from patients with severe infections--the first Ciproxan IV special investigation in 2001].
    Yamaguchi K; Ishii Y; Iinuma Y; Yamanaka K; Ichiyama S; Watanabe N; Uehara N; Kaku M; Kurokawa Y; Hayashi M; Hirakata Y
    Jpn J Antibiot; 2003 Dec; 56(6):546-73. PubMed ID: 15007872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibacterial activity of ciprofloxacin in conventional tests and in a model of bacterial cystitis.
    Greenwood D; Baxter S; Cowlishaw A; Eley A; Slater GJ
    Eur J Clin Microbiol; 1984 Aug; 3(4):351-4. PubMed ID: 6489325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibacterial properties of imipenem with special reference to the activity against methicillin-resistant staphylococci, cefotaxime-resistant Enterobacteriaceae and Pseudomonas aeruginosa.
    Vurma-Rapp U; Kayser FH; Barberis-Maino L
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():27-33. PubMed ID: 3102452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro activity of newer quinolones against aerobic bacteria.
    Auckenthaler R; Michéa-Hamzehpour M; Pechère JC
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative bacteriologic activity of norfloxacin, ofloxacin and pefloxacin against 320 Gram-negative bacilli resistant and non-resistant to nalidixic acid and cephalosporins].
    Croize J; Le Noc P; Bryskier A; Robert J
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):564-8. PubMed ID: 3937128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of ciprofloxacin against gram-positive cocci.
    Barry AL; Jones RN
    Am J Med; 1987 Apr; 82(4A):27-32. PubMed ID: 3578323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
    Jones RN; Pfaller MA;
    Diagn Microbiol Infect Dis; 2001 Apr; 39(4):237-43. PubMed ID: 11404067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.